Self-Emulsifying CBD Formulation Lymphatic Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabidiol (CBD) has low oral bioavailability and inconsistent absorption due to its non-polar nature and high first-pass metabolism in the liver, limiting its effectiveness in treating various medical conditions.
Innovation Solution
A self-emulsifying composition comprising CBD, non-polar solvents like glycerides, and surfactants such as polysorbate 80 and polyoxyl 35 castor oil, which forms oil-in-water emulsions upon dilution, enhancing lymphatic absorption and reducing liver metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cannabidiol is administered orally in conventional formulations, then it is easy to administer, but bioavailability is low and absorption is inconsistent
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by incorporating specific surfactants (polysorbate 80, polyoxyl 35 castor oil) and non-polar solvents (glycerides) to create a self-emulsifying system. This transforms the drug delivery mechanism from direct dissolution to emulsion formation, enabling consistent lymphatic absorption and improving bioavailability reliability while maintaining oral administration convenience
Solution Approach 2:
The patent introduces surfactants and emulsifiers as intermediary substances that facilitate the interaction between the non-polar cannabidiol and aqueous gastrointestinal fluids. These intermediaries enable the formation of stable emulsions that promote lymphatic absorption, thereby consistent bioavailability without compromising ease of oral administration
2Quantity of substance
If cannabidiol is absorbed into the bloodstream, then it reaches systemic circulation, but it undergoes extensive first-pass metabolism in the liver
Solution Approach 1:
The patent segments the absorption pathway by directing cannabidiol absorption through the lymphatic system rather than the portal vein-bloodstream route. This segmentation bypasses the liver's first-pass metabolism, allowing more cannabidiol to reach systemic circulation intact. The self-emulsifying formulation with glycerides and surfactants specifically promotes lymphatic transport of the non-polar cannabinoid
Solution Approach 2:
The patent converts the non-polar nature of cannabidiol, which traditionally causes poor water solubility and inconsistent absorption, into a benefit by leveraging its lipophilicity for lymphatic absorption. The self-emulsifying formulation with non-polar solvents and surfactants transforms the compound's chemical property from a disadvantage into a mechanism for bypassing hepatic metabolism and achieving reliable systemic delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The self-emulsifying composition significantly increases CBD bioavailability, stabilizes its absorption, and allows for better distribution to the central nervous system, reducing food effects and plasma protein binding.
Implementation Method 1
The composition self-emulsifies to form oil-in-water emulsions upon dilution with aqueous media, e.g., water or gastrointestinal fluids
Data Source
AI summary
The disclosure provides self-emulsifying compositions, comprising: (i) an active pharmaceutical ingredient (API) in an amount of 1-15% by weight of the composition; (ii) one or more non-polar solvents in an amount of 20-80% by weight of the composition; and (iii) one or more surfactants in an amount of 15-70% by weight of the composition, wherein the active pharmaceutical ingredient (API) comprises cannabidiol (CBD) and wherein the one or more non-polar solvents comprise a glyceride, together with methods of making and using the same.